SV2009003211A - Cristal novedoso de (s) - (+) - 2 - (2-clorofenil) - 2 - hidroxietil - carbamato ref. tpi5080svpct - Google Patents

Cristal novedoso de (s) - (+) - 2 - (2-clorofenil) - 2 - hidroxietil - carbamato ref. tpi5080svpct

Info

Publication number
SV2009003211A
SV2009003211A SV2009003211A SV2009003211A SV2009003211A SV 2009003211 A SV2009003211 A SV 2009003211A SV 2009003211 A SV2009003211 A SV 2009003211A SV 2009003211 A SV2009003211 A SV 2009003211A SV 2009003211 A SV2009003211 A SV 2009003211A
Authority
SV
El Salvador
Prior art keywords
chlorophenyl
carbamate
hydroxyethyl
ref
new glass
Prior art date
Application number
SV2009003211A
Other languages
English (en)
Inventor
Matthew Peterson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SV2009003211A publication Critical patent/SV2009003211A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON UN CRISTAL NOVEDOSO DE (S)-(+)-2-(2-CLOROFENIL)-2-HIDROXIETIL CARBAMATO, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTE CRISTAL Y MÉTODOS PARA ELABORAR Y UTILIZAR ESTE CRISTAL
SV2009003211A 2006-10-06 2009-04-03 Cristal novedoso de (s) - (+) - 2 - (2-clorofenil) - 2 - hidroxietil - carbamato ref. tpi5080svpct SV2009003211A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82839206P 2006-10-06 2006-10-06

Publications (1)

Publication Number Publication Date
SV2009003211A true SV2009003211A (es) 2009-11-24

Family

ID=39283405

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003211A SV2009003211A (es) 2006-10-06 2009-04-03 Cristal novedoso de (s) - (+) - 2 - (2-clorofenil) - 2 - hidroxietil - carbamato ref. tpi5080svpct

Country Status (19)

Country Link
US (1) US7632963B2 (es)
EP (1) EP2076258A4 (es)
JP (1) JP2010505856A (es)
KR (1) KR20090076958A (es)
CN (1) CN101657195A (es)
AU (1) AU2007307029A1 (es)
BR (1) BRPI0718131A2 (es)
CA (1) CA2665573A1 (es)
CO (1) CO6180504A2 (es)
CR (1) CR10764A (es)
EA (1) EA200970355A1 (es)
GT (1) GT200900076A (es)
IL (1) IL198016A0 (es)
MX (1) MX2009003755A (es)
NI (1) NI200900050A (es)
NO (1) NO20091771L (es)
SV (1) SV2009003211A (es)
WO (1) WO2008045391A2 (es)
ZA (1) ZA200903095B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
WO2013100567A1 (en) * 2011-12-27 2013-07-04 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
KR102399807B1 (ko) * 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법
WO2023014160A1 (ko) * 2021-08-05 2023-02-09 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
CA2349663C (en) 1999-09-10 2006-10-31 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
RS51055B (sr) * 2001-02-27 2010-10-31 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neurodegenerativnih poremećaja
BR0215237A (pt) * 2001-12-21 2004-11-16 Ortho Mcneil Pharm Inc Processo para a preparação de carbamatos de 2-(fenil substituìdo)-2-hidróxi-etila
AU2004265021B2 (en) 2003-08-18 2010-05-27 H. Lundbeck A/S Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
KR20070057939A (ko) * 2004-09-16 2007-06-07 얀센 파마슈티카 엔.브이. 간질형성 및 간질을 치료하는 방법
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
WO2008045391A2 (en) 2008-04-17
US7632963B2 (en) 2009-12-15
CO6180504A2 (es) 2010-07-19
ZA200903095B (en) 2010-07-28
US20080085930A1 (en) 2008-04-10
EP2076258A4 (en) 2011-09-28
CR10764A (es) 2009-09-14
JP2010505856A (ja) 2010-02-25
GT200900076A (es) 2010-05-18
CA2665573A1 (en) 2008-04-17
BRPI0718131A2 (pt) 2013-11-05
AU2007307029A1 (en) 2008-04-17
KR20090076958A (ko) 2009-07-13
CN101657195A (zh) 2010-02-24
NO20091771L (no) 2009-05-05
WO2008045391A3 (en) 2008-06-12
EA200970355A1 (ru) 2009-12-30
NI200900050A (es) 2010-02-01
MX2009003755A (es) 2009-07-10
EP2076258A2 (en) 2009-07-08
IL198016A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
CR10479A (es) Modulares bencimidazolicos de vr1
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY30748A1 (es) Compuesto0s novedosos
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
BRPI0710527B8 (pt) compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
UY31065A1 (es) Heterociclos ciclicos
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
UY30610A1 (es) Moduladores de mglur5
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
SV2009003211A (es) Cristal novedoso de (s) - (+) - 2 - (2-clorofenil) - 2 - hidroxietil - carbamato ref. tpi5080svpct
ECSP099389A (es) Nuevas formas cristalinas
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.
CL2008000287A1 (es) Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades inflamatorias y alergicas de las vias respiratorias.

Legal Events

Date Code Title Description
FD Lapse